Stoke Therapeutics, Inc. Share Price

Equities

STOK

US86150R1077

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 25/06/2024 am IST 5-day change 1st Jan Change
14.33 USD +0.70% Intraday chart for Stoke Therapeutics, Inc. -8.14% +172.43%
Sales 2024 * 1.37Cr 114.57Cr Sales 2025 * 1.63Cr 136.1Cr Capitalization 74Cr 6.19TCr
Net income 2024 * -12Cr -967.46Cr Net income 2025 * -14Cr -1.19TCr EV / Sales 2024 * 37.9 x
Net cash position 2024 * 22Cr 1.84TCr Net cash position 2025 * 12Cr 1.01TCr EV / Sales 2025 * 38 x
P/E ratio 2024 *
-6.26 x
P/E ratio 2025 *
-5.45 x
Employees 110
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.70%
1 week-8.14%
Current month-1.98%
1 month-0.56%
3 months+120.46%
6 months+172.43%
Current year+172.43%
More quotes
1 week
13.65
Extreme 13.65
15.80
1 month
13.45
Extreme 13.45
17.58
Current year
4.09
Extreme 4.09
17.58
1 year
3.35
Extreme 3.35
17.58
3 years
3.35
Extreme 3.35
36.20
5 years
3.35
Extreme 3.35
71.58
10 years
3.35
Extreme 3.35
71.58
More quotes
Managers TitleAgeSince
Founder 52 01/14/01
Chief Executive Officer 75 01/17/01
Chief Tech/Sci/R&D Officer 64 01/17/01
Members of the board TitleAgeSince
Director/Board Member 70 01/15/01
Chief Executive Officer 75 01/17/01
Chairman 63 01/15/01
More insiders
Date Price Change Volume
25/24/25 14.33 +0.70% 639 321
21/24/21 14.23 -3.59% 2,593,998
20/24/20 14.76 -2.06% 551,771
18/24/18 15.07 -3.40% 462,469
17/24/17 15.6 -4.00% 1,061,108

Delayed Quote Nasdaq, June 25, 2024 at 01:30 am IST

More quotes
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.23 USD
Average target price
22.14 USD
Spread / Average Target
+55.61%
Consensus